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Abstract
Objective
To estimate effects of vitamin D levels on incident delirium hospital admissions using inherited
genetic variants in mendelian randomization models, which minimize confounding and exclude
reverse causation.
Methods
Longitudinal analysis using the UK Biobank, community-based, volunteer cohort (2006–2010)
with incident hospital-diagnosed delirium (ICD-10 F05) ascertained during ≤9.9 years of
follow-up of hospitalization records (to early 2016). We included volunteers of European
descent aged 60-plus years by end of follow-up. We used single-nucleotide polymorphisms
previously shown to increase circulating vitamin D levels, and APOE variants. Cox competing
models accounting for mortality were used.
Results
Of 313,121 participants included, 544 were hospitalized with delirium during follow-up. Vi-
tamin D variants were protective for incident delirium: hazard ratio = 0.74 per 10 nmol/L (95%
confidence interval 0.62–0.87, p = 0.0004) increase in genetically instrumented vitamin D, with
no evidence for pleiotropy (mendelian randomization–Egger p > 0.05). Participants with ≥1
APOE e4 allele were more likely to develop delirium (e.g., e4e4 hazard ratio = 3.73, 95%
confidence interval 2.68–5.21, p = 8.0 × 10−15 compared to e3e3), but there was no interaction
with vitamin D variants.
Conclusions and relevance
In a large community-based cohort, there is genetic evidence supporting a causal role for
vitamin D levels in incident delirium. Trials of correction of low vitamin D levels in the
prevention of delirium are needed.
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Delirium is an acute decline in cognitive function, with a rapid
onset of symptoms.1 It is relatively common in later life and is
associated with substantially increased morbidity and
mortality.1,2 Interest has grown in the potential role of vitamin
D in protecting against cognitive decline. A recent meta-
analysis reported that low vitamin D levels are associated with
poorer cognition and accelerated cognitive decline,3 perhaps
through vitamin D’s anti-inflammatory properties.4,5 In ob-
servational studies, low levels of vitamin D have been asso-
ciated with an increased likelihood of delirium in patients with
hip fracture6 and for hospital-acquired, new-onset delirium.7
Genetically increased levels of vitamin D have been linked to
reduced risk of Alzheimer disease in one study.8 However,
evidence for the potential role of genetically increased vitamin
D levels in reducing risk of incident delirium in large
population-based studies is lacking.
Studies of outcomes in later life are susceptible to confounding
and reverse causation, when associations with a risk factor are
due to the effects of underlying pathology rather than being
causal. Inherited genetic variants can provide stronger evidence
for potential causal effect on an outcome—a technique known as
mendelian randomization (MR).9
To apply genetic analyses, variants altering risk factor status
are needed, which have their mode of action through the risk
factor only.9 Here, we applied MR approaches to test vitamin
D associations with incident delirium in an exceptionally large
sample of older UK Biobank participants of European de-
scent, in order to clarify the likely causal significance. We also
accounted for APOE status.
Methods
Between 2006 and 2010, UK Biobank recruited 503,325
community-based volunteers (aged 40–70 years) from across
the United Kingdom.10 Genetic data were available on
488,377 UK Biobank participants, of whom 451,427 partic-
ipants were identified as of European ancestry using self-
report and genetics data.11 Given that 7.5% of the participants
were from non-European ancestries and from diverse line-
ages, we focused on participants from European ancestry.
Standard protocol approvals, registrations,
and patient consents
Participants provided informed consent for data linkage to
hospital inpatient admissions, cancer registrations, and death
registrations. Ethical approval for the UK Biobank study was
obtained from the North West Multi-Centre Research Ethics
Committee. The current analysis was part of UK Biobank–
approved project 14631 on aging well.
Delirium diagnosis was ascertained using ICD-10 code F05 in
hospital discharge data. Participants who had a delirium episode
before baseline interview were excluded from analyses (n = 51).
Participants were eligible for inclusion if they reached the age of
60 within the follow-up period (up to February 16, 2016) (ex-
cluded n = 138,251). Participants with incident delirium had to
be aged 60 years or older at diagnosis because incident cases
before age 60 years are rare (excluded n = 3). One participant
was excluded because they were missing an assessment date.
This left 313,121 participants for the analysis.
Genotyping quality control and imputation were performed
centrally by UK Biobank. Genetic variants rs429358 and
rs7412 were used to define APOE haplotypes. Genetic var-
iants for circulating 25(OH)D concentration (vitamin D)
were extracted from 2 studies: 4 from Vimaleswaran et al.12
and 6 from a more recent report by Jiang et al.,13 which
included a larger sample size but log-transformed the vitamin
D levels (the 4 loci from Vimaleswaran are included in the 6
from Jiang) (only one variant from each locus was included,
and only if the final meta-analysis p value was <5 × 10−8; all
included variants had sufficient imputation quality [>0.4] and
no deviation from Hardy-Weinberg equilibrium [p > 1 ×
10−6] in the UK Biobank participants). We checked for
consistency across both results and used the weights from
Vimaleswaren to obtain the hazard ratio (HR) per nanomoles/
liter of vitamin D. To confirm that the genetic risk score (GRS)
was predictive for vitaminD, we used data from the InCHIANTI
Study, a cohort study of aging in the Tuscany region of Italy in
which both vitamin D and genetic variants were available.
The primary MR analysis methods were performed using R
(v3.4.1) package “MendelianRandomization” (v0.2.2). Ge-
netic variants were individually assessed for their association
with incident delirium, and the natural log-transformed sub-
hazard ratios (sHRs) were aligned with the vitamin D–raising
allele and effect from the previously published studies and
submitted to the “mr_input()” function. We used the pe-
nalized robust inverse-variance weighted (IVW) regression
result as the primary analysis, and checked the penalized
weighted median and penalized robust MR-Egger analyses for
consistency in the effect estimate, and finally whether theMR-
Egger intercept significantly differed from zero to test for
potential pleiotropy (i.e., whether the effect of the single-
nucleotide polymorphisms [SNPs] on delirium is via a path-
way other than the risk factor under assessment14). The
exponential of the IVW regression coefficient was derived
Glossary
CI = confidence interval; GRS = genetic risk score; HR = hazard ratio; ICD-10 = International Classification of Diseases, Tenth
Revision; IVW = inverse-variance weighted; MR = mendelian randomization; pQTL = protein quantitative trait loci; sHR =
subhazard ratio; SNP = single-nucleotide polymorphism.
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(due to the earlier logging of the estimates for the MR analysis)
to give the risk change (HR) per unit of vitamin D (nmol/L).
TheUKNational Institute for Clinical Excellence concluded that
“there is consensus that levels below 25 nmol/L (10 ng/ml)
qualify as ‘deficient,’ but beyond this there is currently no stan-
dard definition of ‘optimal’ 25(OH)D levels. Some sources
suggest that levels above 50 nmol/L (30 ng/ml) are ‘sufficient,’
while 70–80 nmol/L (28–32 ng/ml) is ‘optimal.’”15 We there-
fore chose to present the effect of genetically instrumented vi-
tamin D levels per 10 nmol/L increase, as this is a clinically
relevant level. To derive the risk of incident delirium per 10
nmol/L of vitamin D, we raised the HR to the power 10.
In secondary analyses of vitamin D, we created a GRS by
summing the number of vitamin D-increasing alleles carried
by each UK Biobank participant, weighted by the effect on
circulating vitamin D levels using PLINK v1.916; we used the
6 loci from Jiang et al.13 We confirmed that our vitamin D
GRSwas associated with vitaminD levels in blood assays from
1,161 participants from the InCHIANTI aging study, using
a linear regression model adjusted for age, sex, and study site,
with natural log-transformed vitamin D levels as the outcome
(coefficient = 1.29, 95% confidence interval [CI] 0.80–1.78,
p = 3 × 10−7).
Estimates of associations between the vitamin D variants and
incident delirium were from Fine and Gray competing risks
regression17 adjusted for age, sex, genotyping array, and principal
components 1–5 of the genotyping data to account for pop-
ulation structure. Estimates of associations between APOE
haplotype and incident delirium were adjusted for age, sex,
genotyping array, and principal components 1–5. In sensitivity
analyses, we investigated the effects of adjusting for self-reported
time spent in the sun in the summer, excluding one of each pair
of participants related to the third degree or closer (identified by
KING kinship analysis18), adjusting for calcium GRS (n = 5 of 7
variants published in reference 19 as rs1550532 were not avail-
able in the UK Biobank version 2 genetic data release, and we
excluded rs1570669 because it is located at the same locus as
rs6013897 in the vitamin D score on chromosome 20), ex-
cluding participants with diagnosed dementia from analyses
(ICD-10 codes F00, F01, F02, F03, and G30), investigating the
effect of a rare variant inCYP2R1 (rs117913124)20 with incident
delirium, and rerunning the analysis using a noncompeting risk
Cox model. To investigate whether the vitamin D-increasing
variants may be acting via other pathways, we first took advan-
tage of recent large pQTL (protein quantitative trait loci) studies
to determine whether these loci are associated with proteins
other than vitamin D21,22 and, second, the catalog of published
genome-wide association studies.23 Stata v14.1 (StataCorp,
College Station, TX) was used for competing risks regression.
Data availability
Data are available from the UK Biobank after submitting an
application (ukbiobank.ac.uk/register-apply/). The syntax for
conducting the analysis is available on request.
Results
Of 313,121 participants included in analyses, 544 had at least
one incident episode of delirium recorded in hospital dis-
charge data. The mean time to delirium diagnosis was 4.6
years (SD 1.6 years). Mean age at baseline for all the partic-
ipants was 61.7 years (SD 4.7 years) and 53.8% of the sample
were women (table 1). The mean age at delirium diagnosis
was 71.6 years (SD 4.12 years), the minimum and maximum
age was 60.0 and 77.8 years, respectively. The overall follow-
Table 1 Characteristics of the sample
All Participants with incident delirium Nondelirium controls
No. (%) 313,121 544 312,577
Age, y, mean (SD) at baseline 61.7 (4.7) 64.9 (4.0) 61.7 (4.7)
Female, n (%) 168,505 (53.8) 208 (38.2) 168,297 (53.8)
Prevalent dementia, n (%) 150 (0.1) 6 (1.1) 144 (0.1)
Mean no. of 25(OH)D-increasing allelesa 0.269 (0.068) 0.269 (0.068) 0.260 (0.072)
APOE haplotype, n (%)
«2«2 1,965 (0.6) 3 (0.6) 1,962 (0.6)
«2«3 38,753 (12.4) 54 (9.9) 38,699 (12.4)
«2«4 7,800 (2.5) 13 (2.4) 7,787 (2.5)
«3«3 183,295 (58.5) 266 (48.9) 183,029 (58.6)
«3«4 73,882 (23.6) 168 (30.9) 73,714 (23.6)
«4«4 7,412 (2.4) 40 (7.4) 7,372 (2.4)
a These are from the genetic risk score weighted for the effect of each variant on 25(OH)D levels.
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up was up to 9.9 years. There were 11,669 deaths during the
follow-up period (198 deaths after delirium). Within 1 year
after the delirium diagnosis, 151 (27.8%) had died, and within
5 years, 196 (36.3%) had died.
Vitamin D-increasing alleles were associated with decreased
risk of delirium (figure, A and B and table 2): the IVW re-
gression coefficient was −1.65 (95%CI −2.03 to −1.27, p = 3.5
× 10−17) (table 3). We observed consistent effect directions in
the other MR methods (penalized weighted median co-
efficient = −1.71, 95% CI −3.04 to −0.38) (penalized robust
MR-Egger coefficient = −1.90, 95% CI −2.61 to −1.19), and
no significant pleiotropy, as tested by the MR-Egger method
(p > 0.05).
Because the units from Jiang et al. are natural log-transformed
vitamin D levels and therefore are not easily interpretable, we
also applied MR methods to the 4 largest-effect variants
published by Vimaleswaran et al.12 who provide the per-allele
effect on each nanomole/liter of vitamin D levels. This
relationship was consistent when we used 4 vitamin D-increasing
alleles fromVimaleswaran et al.12 (table 3). The sHR for incident
delirium per unit increase in genetically instrumented 25(OH)D
levels (nmol/L) was 0.970 (the exponential of the penalized
Table 2 Six vitamin D–raising genetic variant associations with incident delirium
Gene SNP CHR POS EA OA EAF
Vitamin D associationa Delirium associationb
β (95% CI) p Value sHR (95% CI) p Value
GC rs3755967 4 72828262 C T 0.71 0.089 (0.085–0.094) 4.7 × 10−300 0.860 (0.754–0.980) 0.024
CYP2R1 rs10741657 11 14871454 A G 0.40 0.031 (0.027–0.036) 2.1 × 10−46 0.947 (0.839–1.069) 0.380
NADSYN1/DHCR7 rs12785878 11 70845097 T G 0.21 0.036 (0.032–0.040) 3.8 × 10−62 0.938 (0.810–1.086) 0.390
AMDHD1 rs10745742 12 94882660 T C 0.62 0.017 (0.012–0.021) 1.9 × 10−14 0.873 (0.770–0.989) 0.033
SEC23A rs8018720 14 38625936 G C 0.18 0.016 (0.011–0.022) 4.7 × 10−9 0.997 (0.856–1.160) 0.960
CYP24A1 rs17216707 20 52165769 T C 0.81 0.026 (0.021–0.031) 8.1 × 10−23 0.974 (0.838–1.131) 0.730
Abbreviations: β = per-allele effect on log-transformed nmol/L of 25(OH)D; CHR = chromosome; CI = confidence interval; EA = effect allele (vitamin
D-increasing); EAF = effect allele frequency in UK Biobank sample included in analyses; OA = other allele; POS = position on genome build 37; sHR = per
additional effect allele subhazard ratio on risk of incident delirium; SNP = single-nucleotide polymorphism.
a Summary statistics from Jiang et al.13 (2018).
b Summary statistics from the current study.
Figure Vitamin D-increasing genetic variants are associated with reduced risk of incident delirium
Jiang et al.13 (2018) found 6 genetic variants to affect circulating 25(OH)D (vitamin D) levels. (A) The effect of previously published per-allele effect of each
variant on vitamin D levels is plotted on the x-axis, and the association of the same variant with incident delirium (logged hazard ratio) is plotted on the y-axis,
with themendelian randomization inverse-weighted (MR-IVW) regression line and 95% confidence intervals (CIs) also show. (B) The per-allele associationwith
incident delirium is shown for each vitamin D–raising genetic variant, with a random-effects (RE) meta-analysis of the 6 variants also shown. sHR = subhazard
ratio.
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robust IVW regression coefficient −0.0307; table 3) (95% CI
0.953–0.986): incident delirium risk is therefore reduced by 3%
per nmol/L increase in genetically instrumented vitamin D. The
risk reduction per 10 nmol/L increase was 0.736 (95% CI
0.620–0.873), calculated by raising 0.970 to the power 10. We
observed consistent effect directions in the other MR methods
(penalized weightedmedian sHR = 0.968, 95%CI 0.938–0.998)
(penalized robust MR-Egger sHR = 0.970, 95% CI
0.951–0.990), and no significant pleiotropy, as tested by theMR-
Egger method (p > 0.05) (table 3). Using a GRS for vitamin D,
we found a consistent association (sHR = 0.88 per SD of vitamin
D GRS, 95% CI 0.81–0.96, p = 0.0044).
Participants with one or more APOE e4 allele were at a sub-
stantial increased risk of incident delirium (table 4). Those
homozygote for APOE e4 (i.e., 2 e4 copies present) had
markedly increased risks (sHR = 3.73, 95% CI 2.68–5.21, p =
8.0 × 10−15); e4 heterozygotes (i.e., e3e4) were at intermediate
risk (sHR = 1.58, 95%CI 1.30–1.91, p = 3.8 × 10−6). The APOE
associations were independent of the vitaminD genetic risks and
Table 3 MR results for the vitamin D–raising genetic variants against incident delirium
MR methoda β (95% CI) p Value sHRb (95% CI)
Four vitamin D variants from Vimaleswaran 2013 (nmol/L)c
IVW −0.0307 (−0.0477 to
−0.0137)
4.0 × 10−4 0.970
(0.953–0.986)
Weighted median −0.0326 (−0.0636 to
−0.0017)
3.9 × 10−2 0.968
(0.938–0.998)
MR-Egger −0.0302 (−0.0507 to
−0.0097)
3.9 × 10−3 0.970
(0.951–0.990)
MR-Egger (intercept) −0.0013 (−0.0756 to 0.073) 9.7 × 10−1 0.999
(0.927–1.076)
Six vitaminDvariants from Jiang et al.13 (2018) (natural log-transformednmol/L)d
IVW −1.6521 (−2.0303 to
−1.2739)
3.5 × 10−17
Weighted median −1.7067 (−3.0376 to
−0.3759)
1.2 × 10−2
MR-Egger −1.9003 (−2.6117 to
−1.1888)
2.1 × 10−7
MR-Egger (intercept) 0.0147 (−0.0372 to 0.0666) 5.8 × 10−1
Abbreviations: CI = confidence interval; IVW = inverse-variance weighted; MR = mendelian randomization; sHR = subhazard ratio.
a MR methods = penalized robust.
b sHR: risk of incident delirium per nmol/L increase in genetically instrumented vitamin D (25[OH]D) levels.
c β = log(HR) against 25(OH)D levels (nmol/L).
d β = log(HR) against 25(OH)D levels (natural log-transformed nmol/L); sHR only included for the Vimaleswaran effect because those based on the Jiang results
could be misleading (because of the vitamin D levels being natural log-transformed).
Table 4 APOE haplotype associations with delirium
APOE haplotypea sHR (95% CI) p Value
Adjusted for vitamin D GRSb
sHR (95% CI) p Value
«2«2 1.07 (0.34–3.35) 9.0 × 10−1 1.08 (0.35–3.36) 9.0 × 10−1
«2«3 0.96 (0.72–1.29) 7.9 × 10−1 0.96 (0.72–1.29) 7.9 × 10−1
«2«4 1.16 (0.67–2.03) 6.0 × 10−1 1.17 (0.67–2.04) 5.9 × 10−1
«3«3 1 1
«3«4 1.58 (1.3–1.91) 3.8 × 10−6 1.58 (1.3–1.92) 3.5 × 10−6
«4«4 3.73 (2.68–5.21) 8.0 × 10−15 3.74 (2.69–5.22) 7.0 × 10−15
Abbreviations: CI = confidence interval; GRS = genetic risk score; sHR = subhazard ratio.
a e1e2 and e1e4 not reported because of low numbers and no participants with incident delirium.
b Vitamin D genetic risk score (6 variants) sHR 0.88 (95% CI 0.81–0.96), p value 3.80e-03.
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were not substantively changed (table 4). There was no in-
teraction with vitamin D variants.
Sensitivity analyses
To test the robustness of the vitamin D association with de-
lirium, we adjusted for self-reported time spent outdoors in
the summer; excluded one of each pair of participants related
to the third degree or closer; and adjusted for a GRS of 5
known calcium level–altering variants that have not been
reported to be associated with vitamin D levels. Results were
not substantively changed (table 5) and the calcium-altering
variants were not associated with delirium. Excluding 150
cases of dementia diagnosed before the assessment visit had
no effect on the association between the vitamin D GRS,
APOE genotype, and incident delirium (table 5). We tested
the association between a low-frequency variant in CYP2R1
(rs117913124, vitamin D–decreasing minor allele frequency
2.77% in the studied sample) identified in a separate study19
and incident delirium, and found there was no significant
association (sHR 1.05, 95%CI 0.74–1.49, p = 0.78). However,
because we had only 80% power to detect an effect of 1.6 (at
α = 0.05, with 544 patients with delirium and 312,577 con-
trols, using the genetic association study power calculator24),
this variant may have a smaller effect on delirium that we were
not powered to detect. In noncompeting risk models, the
point estimates for the 6 vitamin D genetic variants with
incident delirium were slightly different, although the overall
conclusion remained the same (rs3755967 HR 0.86, 95% CI
0.76–0.98; rs10745742 HR 0.87, 95% CI 0.77–0.99;
rs12785878 HR 0.94, 95% CI 0.81–1.08; rs10741657 HR
1.06, 95% CI 0.93–1.19; rs17216707 HR 1.03, 95% CI
0.88–1.19; rs8018720 HR 1.00, 95% CI 0.86–1.17). The MR
analyses using results from noncompeting risk models were
also consistent when using the 4 variants from Vimaleswaran:
the HR for incident delirium per 10 nmol/L increase in ge-
netically instrumented 25(OH)D levels was 0.737 (95% CI
0.620–0.872). Finally, we found that vitamin D-increasing loci
(or proxies) are not associated with other protein levels in 2
recent large pQTL studies,21,22 although one of the 6 SNPs
(rs17216707) is also associated with estimated glomerular
filtration rate.25 Excluding this SNP from the MR analysis
makes no meaningful difference (new penalized robust MR-
IVW regression estimate using only 5 variants = −1.6399, 95%
CI −1.887 to −1.392, p = 1.4 × 10−38).
Discussion
In this large-scale prospective study, participants with genet-
ically determined higher vitamin D levels had substantially
lower risks of incident hospitalized episodes of delirium. Be-
cause MR analysis greatly reduces confounding and excludes
reverse causation,9,13 our results suggest that interventional
trials to increase vitamin D levels may be justified to reduce
risk of delirium. In addition, participants carrying an APOE e4
allele were at increased risk of incident delirium, likely con-
tributing to the increased risk of dementia observed after an
episode of delirium. However, the effect of vitamin D–related
variants was not altered by APOE status.
The association between vitamin D and delirium is plausible as
vitamin D receptors are distributed within the hippocampus,
hypothalamus, cortex, and subcortex, and evidence suggests
Table 5 Hazard ratios for incident deliriumusing a vitaminDgenetic risk score and APOE following a number of sensitivity
analyses
Exposure Analysis sHR (95% CI) p Value
Vitamin D genetic risk score (6 variants)
Adjustment for time spent outdoors in the summer (n = 295,049) 0.89 (0.82–0.97) 1.1 × 10−2
Unrelated participants (n = 262,560) 0.90 (0.82–0.98) 2.1 × 10−2
Adjustment for calcium genetic risk score (5 variants) 0.88 (0.81–0.96) 4.4 × 10−3
Excluding prevalent dementia (n = 150) at baseline 0.88 (0.80–0.96) 3.8 × 10−3
APOE haplotypea excluding prevalent
dementia (n = 150) at baseline
e2e2 1.09 (0.35–3.40) 8.8 × 10−1
e2e3 0.96 (0.71–1.28) 7.7 × 10−1
e2e4 1.18 (0.68–2.06) 5.6 × 10−1
e3e3 1
e3e4 1.59 (1.31–1.93) 2.7 × 10−6
e4e4 3.80 (2.73–3.80) 3.6 × 10−15
Abbreviations: CI = confidence interval; sHR = subhazard ratio.
a e1e2 and e1e4 not reported because of low numbers and no participants with incident delirium.
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a variety of neurophysiologic and neuroprotective mecha-
nisms.26 In addition, behavioral and attention disorders, and
accelerated aging have been documented in vitamin D receptor
knockout transgenic mice models.27–29 Furthermore, evidence
indicates that vitamin D may modulate serotonin synthesis.30
Serotonin is involved in regulating a range of behaviors and
brain function and has been indicted to have a role in de-
lirium.31 Therefore, the effect of vitamin D on delirium may be
in part attributable to its effect on serotonin synthesis.30,31 Low
levels of vitaminD have been observationally associated with an
increased likelihood of delirium in patients with hip fracture and
for hospital-acquired, new-onset delirium.6,7
A number of studies have usedMR approaches to estimate the
effects of low vitamin D levels on cognitive outcomes. Of
note, a recent analysis showed no association between vitamin
D and global or memory cognition using an MR approach,
although the vitamin D score (synthesis) was composed of 2
SNPs.29 Genetically increased levels of vitamin D (4 SNPs
score), however, were associated with a reduced risk of Alz-
heimer disease at nominal statistical significance.8 Here, we
use MR approaches to estimate the effects of vitamin D levels
on risk of delirium, thereby minimizing confounding and
excluding reverse causation. Although we cannot rule out
pleiotropy (the vitamin D-increasing loci affect delirium risk
via other mechanistic routes), we found no evidence in 2 large
recent pQTL studies21,22 that these loci affect other protein
levels, and excluding the one variant associated with estimated
glomerular filtration rate in another genome-wide association
study25 did not significantly change the result.
A recent meta-analysis reported that there was no association
between APOE and delirium, although the number of de-
lirium cases included was smaller than in the present study.28
Here, we showed carriers of an APOE e4 allele were at an
increased risk of delirium independent of a dementia di-
agnosis in our analyses, suggesting that APOE may con-
stitute a shared mechanism between the 2 conditions.
APOE e4 status may therefore be a useful addition to es-
timating risk of developing delirium, especially in designing
intervention trials.
There are a number of limitations with our study. First, serum
vitamin D levels were not available for the UK Biobank par-
ticipants and therefore the genetic variants could not be
assessed concurrently with vitamin D levels and delirium.
However, we confirmed that the genetic variants we studied
were strongly associated with blood levels of vitamin D in the
InCHIANTI Study (see methods). Second, MR analysis has
important assumptions and limitations, in particular that the
genetic instruments are only associated with the outcome via
the exposure under examination, and the association between
the exposure and outcome is linear; however, MR-Egger
analysis provided no evidence of pleiotropy, and variants were
not associated with covariates in our analyses. Finally, UK
Biobank participants tended to be healthier than the UK
general population at baseline, and therefore our number of
delirium cases is lower than expected and estimates may be
less applicable to frail older groups.32
In the data available, the vast majority of the participants had
one delirium episode; 32 participants had ≥2 delirium epi-
sodes. Our analysis is based on the first delirium episode.
Future studies could examine risk factors for recurrent events.
The methods in this analysis were used to estimate the linear
effect of vitamin D levels around the population average; fu-
ture studies could examine the nonlinear effects of vitamin D
and delirium.
In this study, genetic evidence suggests that higher vitamin D
levels may be a substantial causal protective factor for incident
delirium. Clinical studies are needed to confirm this. Delirium
and dementia share a common risk factor in APOE genotype,
which may contribute to the high rates of incident dementia
observed after an episode of delirium.
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